Cargando…

BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes

BACKGROUND: Patients with cardiovascular disease (CVD) and type 2 diabetes (DM2) have a high residual risk for experiencing a major adverse cardiac event. Dysregulation of epigenetic mechanisms of gene transcription in innate immune cells contributes to CVD development but is currently not targeted...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wasiak, Sylwia, Dzobo, Kim E., Rakai, Brooke D., Kaiser, Yannick, Versloot, Miranda, Bahjat, Mahnoush, Stotz, Stephanie C., Fu, Li, Sweeney, Michael, Johansson, Jan O., Wong, Norman C. W., Stroes, Erik S. G., Kroon, Jeffrey, Kulikowski, Ewelina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7657365/ https://www.ncbi.nlm.nih.gov/pubmed/33172487 http://dx.doi.org/10.1186/s13148-020-00943-0

Ejemplares similares

Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism
por: Tsujikawa, Laura M., et al.
Publicado: (2019)

Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)
por: Wasiak, Sylwia, et al.
Publicado: (2017)

APABETALONE (RVX-208) REDUCES ACE2 PROTEIN ABUNDANCE AND PREVENTS SARS-COV-2 SPIKE PROTEIN BINDING TO HUMAN LUNG CELLS, A MOA THAT COULD ATTENUATE VIRAL ENTRY
por: Fu, Li, et al.
Publicado: (2021)

Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes
por: Wasiak, Sylwia, et al.
Publicado: (2016)

Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro
por: Gilham, Dean, et al.
Publicado: (2021)

Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells
por: Sarsons, Christopher D., et al.
Publicado: (2023)

RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist
por: McLure, Kevin G., et al.
Publicado: (2013)

RVX 208
Publicado: (2012)

Benefit of Apabetalone on Plasma Proteins in Renal Disease
por: Wasiak, Sylwia, et al.
Publicado: (2017)

Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular Disease
por: Wasiak, Sylwia, et al.
Publicado: (2020)

Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy
por: Fu, Li, et al.
Publicado: (2022)

Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment
por: Gilham, Dean, et al.
Publicado: (2023)

Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation
por: Fu, Li, et al.
Publicado: (2023)

BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency
por: Lu, Panpan, et al.
Publicado: (2017)

Bromodomain and extraterminal (BET) protein inhibitor, apabetalone, reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro
por: Gilham, D, et al.
Publicado: (2021)

More Insights into the Association between RVX-208 and Pulmonary Arterial Hypertension
por: Ning, Dong, et al.
Publicado: (2020)

Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Reply to Ning et al.: More Insights into the Association between RVX-208 and Pulmonary Arterial Hypertension
por: Provencher, Steeve, et al.
Publicado: (2020)

Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease
por: Toth, Peter P., et al.
Publicado: (2022)

Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study
por: Nicholls, Stephen J., et al.
Publicado: (2021)

Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations
por: Wang, Qianqian, et al.
Publicado: (2017)

ABCA1 overexpression worsens colorectal cancer prognosis by facilitating tumour growth and caveolin‐1‐dependent invasiveness, and these effects can be ameliorated using the BET inhibitor apabetalone
por: Aguirre‐Portolés, Cristina, et al.
Publicado: (2018)

Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases
por: Kulikowski, Ewelina, et al.
Publicado: (2020)

Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a)
por: Stiekema, Lotte C A, et al.
Publicado: (2020)

Targeting the Non-catalytic RVxF Site of Protein Phosphatase-1 With Small Molecules for Ebola Virus Inhibition
por: Lin, Xionghao, et al.
Publicado: (2019)

The Complex Interplay between DNA Injury and Repair in Enzymatically Induced Mutagenesis and DNA Damage in B Lymphocytes
por: Bahjat, Mahnoush, et al.
Publicado: (2017)

Small Molecules Targeted to a Non-Catalytic “RVxF” Binding Site of Protein Phosphatase-1 Inhibit HIV-1
por: Ammosova, Tatiana, et al.
Publicado: (2012)

To Bet or Not to Bet on T-bet As a Therapeutic Target in Emphysema?
por: Wang, Xiaoyun, et al.
Publicado: (2019)

Cantata no. 208 Was mir behagt : Hunt cantata /
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1986)

Directed Flow in 158 A GeV $^{208}Pb$ + $^{208}Pb$ Collisions
por: Aggarwal, M.M., et al.
Publicado: (1998)

Particle production in 158.A GeV $^{208}$Pb + $^{208}$Pb collisions
por: Awes, T C
Publicado: (1999)

Bromodomain and Extra Terminal (BET) Inhibitor Suppresses Macrophage-Driven Steroid-Resistant Exacerbations of Airway Hyper-Responsiveness and Inflammation
por: Nguyen, Thi Hiep, et al.
Publicado: (2016)

Small Molecule BRD4 Inhibitors Apabetalone and JQ1 Rescues Endothelial Cells Dysfunction, Protects Monolayer Integrity and Reduces Midkine Expression
por: Shahid, Sidra, et al.
Publicado: (2022)

Compton scattering on $^{208}$Pb
por: Alberico, W M, et al.
Publicado: (1982)

Oral Presentations 208–237
Publicado: (2001)

Competition between Allowed and First-Forbidden $β$ Decay: The Case of $^{208}$Hg$→^{208}$Tl
por: Carroll, R J, et al.
Publicado: (2020)

Freeze-Out Parameters in Central 158 AGeV $^{208}Pb$ + $^{208}Pb$ Collisions
por: Aggarwal, M.M., et al.
Publicado: (1999)

Direct Photon Production in 158 A GeV $^{208}Pb+^{208}Pb$ collisions
por: Aggarwal, M.M., et al.
Publicado: (2001)

Direct Photon Production in 158 A GeV $^{208}$ PB+$^{208}$ PB Collisions
por: Peitzmann, Thomas
Publicado: (2001)

Prolonged hematopoietic and myeloid cellular response in patients after an acute coronary syndrome measured with (18)F-DPA-714 PET/CT
por: Verweij, Simone L., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ls1tam6q5t8u0gkon8fcs4thqa